DDIT3 and mantle cell lymphoma: Other combination studies include idelalisib in combination with obinutuzumab in FL (NCT03890289) or WM [63], duvelisib with acalabrutinib in B-NHL (NCT04836832), umbralisib with rituximab in FL/MCL (NCT03919175), with ublituximab in FL (NCT03828448) or with ublituximab-CHOP in MCL (NCT04692155).